{"id":"NCT00751621","sponsor":"CSL Behring","briefTitle":"Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)","officialTitle":"A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2008-09-12","resultsPosted":"2013-01-25","lastUpdate":"2014-04-02"},"enrollment":40,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"IgPro20","otherNames":["IgG with Proline (IgPro)","Hizentra"]}],"arms":[{"label":"IgPro20","type":"EXPERIMENTAL"}],"summary":"This study is a continuation of the study ZLB06\\_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.","primaryOutcome":{"measure":"Total Serum IgG Trough Levels","timeFrame":"Up to 42 months","effectByArm":[{"arm":"IgPro20","deltaMin":7.97,"sd":1.171}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":13,"countries":["France","Germany","Poland","Romania","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["24412910"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":40},"commonTop":["Bronchitis","Upper respiratory tract infection","Sinusitis","Nasopharyngitis","Cough"]}}